BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng Z, Yang B, Liao Z. Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. Front Oncol 2021;11:650481. [PMID: 33777812 DOI: 10.3389/fonc.2021.650481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jian D, Qian C, Wang D, Ma Q, Wang L, Li C, Xu M, Dai N, Chen Q, He J, Zhang H, Yuan M, Chen R, Chao R, Feng Y. Conversion therapy with tislelizumab for high microsatellite instability, unresectable stage III gastric cancer: a case report. Ann Transl Med 2021;9:1489. [PMID: 34734041 DOI: 10.21037/atm-21-4295] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Du F, Liu Y. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. J Clin Lab Anal 2021;:e24141. [PMID: 34817097 DOI: 10.1002/jcla.24141] [Reference Citation Analysis]
3 Guo XJ, Lu JC, Zeng HY, Zhou R, Sun QM, Yang GH, Pei YZ, Meng XL, Shen YH, Zhang PF, Cai JB, Huang PX, Ke AW, Shi YH, Zhou J, Fan J, Chen Y, Yang LX, Shi GM, Huang XY. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. Front Immunol 2021;12:705378. [PMID: 34526987 DOI: 10.3389/fimmu.2021.705378] [Reference Citation Analysis]
4 Nie C, Lv H, Liu Y, Chen B, Xu W, Wang J, Chen X. Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study. Front Oncol 2021;11:741865. [PMID: 34631579 DOI: 10.3389/fonc.2021.741865] [Reference Citation Analysis]